Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation

Abstract Due to progressive abdominal-venous congestion severe tricuspid regurgitation (TR) is a common cause of cardiorenal and cardiohepatic syndrome. We initiated the TRICAVAL study to compare interventional valve implantation into the inferior vena cava (CAVI) versus optimal medical therapy (OMT...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bernd Hewing, Isabel Mattig, Fabian Knebel, Verena Stangl, Michael Laule, Karl Stangl, Henryk Dreger
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2ccfbf884d26457489b8d3f69d863641
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2ccfbf884d26457489b8d3f69d863641
record_format	dspace
spelling	oai:doaj.org-article:2ccfbf884d26457489b8d3f69d8636412021-11-14T12:20:24ZRenal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation10.1038/s41598-021-01322-22045-2322https://doaj.org/article/2ccfbf884d26457489b8d3f69d8636412021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-01322-2https://doaj.org/toc/2045-2322Abstract Due to progressive abdominal-venous congestion severe tricuspid regurgitation (TR) is a common cause of cardiorenal and cardiohepatic syndrome. We initiated the TRICAVAL study to compare interventional valve implantation into the inferior vena cava (CAVI) versus optimal medical therapy (OMT) in severe TR. In the present subanalysis, we aimed to evaluate the effects of CAVI on clinical signs of congestion, renal and hepatic function. TRICAVAL was an investigator-initiated, randomized trial. Twenty-eight patients with severe TR were randomized to OMT or CAVI using an Edwards Sapien XT valve. Probands who completed the 3-month follow-up (CAVI [n = 8], OMT [n = 10]) were evaluated by medical history, clinical examination, and laboratory testing at baseline, 3 and 12 months. After 3 months, the CAVI group exhibited a significant reduction of body weight (from 80.7 [69.0–87.7] kg to 75.5 [63.8–84.6] kg, p < 0.05) and abdominal circumference (from 101.5 ± 13.8 cm to 96.3 ± 15.4 cm, p ≤ 0.01) and a trend to lower doses of diuretics compared to OMT. Renal and hepatic function parameters did not change significantly. Within a short-term follow-up, CAVI led to an improvement of clinical signs of venous congestion and a non-significant reduction of diuretic doses compared to OMT.Bernd HewingIsabel MattigFabian KnebelVerena StanglMichael LauleKarl StanglHenryk DregerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bernd Hewing Isabel Mattig Fabian Knebel Verena Stangl Michael Laule Karl Stangl Henryk Dreger Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
description	Abstract Due to progressive abdominal-venous congestion severe tricuspid regurgitation (TR) is a common cause of cardiorenal and cardiohepatic syndrome. We initiated the TRICAVAL study to compare interventional valve implantation into the inferior vena cava (CAVI) versus optimal medical therapy (OMT) in severe TR. In the present subanalysis, we aimed to evaluate the effects of CAVI on clinical signs of congestion, renal and hepatic function. TRICAVAL was an investigator-initiated, randomized trial. Twenty-eight patients with severe TR were randomized to OMT or CAVI using an Edwards Sapien XT valve. Probands who completed the 3-month follow-up (CAVI [n = 8], OMT [n = 10]) were evaluated by medical history, clinical examination, and laboratory testing at baseline, 3 and 12 months. After 3 months, the CAVI group exhibited a significant reduction of body weight (from 80.7 [69.0–87.7] kg to 75.5 [63.8–84.6] kg, p < 0.05) and abdominal circumference (from 101.5 ± 13.8 cm to 96.3 ± 15.4 cm, p ≤ 0.01) and a trend to lower doses of diuretics compared to OMT. Renal and hepatic function parameters did not change significantly. Within a short-term follow-up, CAVI led to an improvement of clinical signs of venous congestion and a non-significant reduction of diuretic doses compared to OMT.
format	article
author	Bernd Hewing Isabel Mattig Fabian Knebel Verena Stangl Michael Laule Karl Stangl Henryk Dreger
author_facet	Bernd Hewing Isabel Mattig Fabian Knebel Verena Stangl Michael Laule Karl Stangl Henryk Dreger
author_sort	Bernd Hewing
title	Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
title_short	Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
title_full	Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
title_fullStr	Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
title_full_unstemmed	Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
title_sort	renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2ccfbf884d26457489b8d3f69d863641
work_keys_str_mv	AT berndhewing renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT isabelmattig renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT fabianknebel renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT verenastangl renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT michaellaule renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT karlstangl renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation AT henrykdreger renalandhepaticfunctionofpatientswithseveretricuspidregurgitationundergoinginferiorcavalvalveimplantation
_version_	1718429277056139264

Renal and hepatic function of patients with severe tricuspid regurgitation undergoing inferior caval valve implantation

Ejemplares similares